EP. 1: ACTRIMS 2020 News Network: CLARITY Study on Relapsing Multiple Sclerosis
EP. 2: ACTRIMS 2020 News Network: Updated Data From the CLARITY Study
EP. 3: ACTRIMS 2020 News Network: EXPAND Study on Relapsing MS
EP. 4: ACTRIMS 2020 News Network: Effect of Disease Duration in the EXPAND Study
EP. 5: ACTRIMS 2020 News Network: OPERA I/II Trials on Relapsing MS
EP. 6: ACTRIMS 2020 News Network: 6-Year Data With Ocrelizumab
EP. 7: ACTRIMS 2020 News Network: APLIOS Bioequivalence Study on Relapsing MS
EP. 8: ACTRIMS 2020 News Network: B-Cell Depletion in the Phase 2 APLIOS Study
EP. 9: ACTRIMS 2020 News Network: Updated Recommendations for Standardized MRI Protocol in MS
EP. 10: ACTRIMS 2020 News Network: Standardized MRI Protocol for MS
EP. 11: ACTRIMS 2020 News Network: An Overview of Other Exciting Data
EP. 12: Immunosuppressive DMTs Associated With Longer COVID-19 Hospitalization in Patients With Multiple Sclerosis
Investigators caution health care providers to consider specific risks of severe COVID-19 infection before initiating this therapy.